Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Core Insights - Serina Therapeutics has initiated dosing for the first patient in its Phase 1b registrational clinical trial for SER-252, targeting advanced Parkinson's disease [1][3][4] - The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of SER-252 in patients whose symptoms are not adequately managed by existing therapies [2][8] - The company expects to advance to Cohort 2 following a blinded evaluation by the Safety Monitoring Committee in the third quarter of 2026 [1][2] Company Overview - Serina Therapeutics is a clinical-stage biotechnology firm focused on developing drug candidates for neurological diseases using its proprietary POZ Platform [5] - The POZ Platform enhances drug efficacy and safety profiles across various modalities, including small molecules and RNA-based therapeutics [6] - The company is headquartered in Huntsville, Alabama, and collaborates with Parkinson's Australia and Neuroscience Trials Australia for patient enrollment [3][5] Product Details - SER-252 is an investigational therapy designed to provide continuous dopaminergic stimulation, potentially reducing levodopa-related motor complications in Parkinson's disease [8] - The POZ technology utilized in SER-252 aims to improve pharmacokinetic profiles, addressing issues like toxicity and short half-life associated with existing treatments [6][8] - The company has established partnerships, including a non-exclusive license agreement with Pfizer for the use of its POZ polymer technology in lipid nanoparticle drug delivery [7]